Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

BioMarck Pharmaceuticals Announces the Issuance of Two U. S. Patents For Treatment Of COPD

By Pharmaceutical Processing | June 16, 2009

BioMarck Pharmaceuticals, a research and development company involved in the treatment of respiratory diseases, has announced that the United States Patent and Trademark Office has issued two new patents enhancing its intellectual property portfolio in support of its current lead drug for the treatment of COPD. One of the two issued U.S. patents (No. 7,524,926), titled “Mucin Hypersecretion Inhibitors and Methods of Use,” provides broad protection for BioMarck’s lead drug, BIO-11006 Inhalation Solution, as well as a series of other first-in-class mucus inhibiting peptides. This patent will provide protection for BioMarck’s lead drug at least until 2026. The second U.S. patent (No. 7,544,772), titled “Methods for Regulating Inflammatory Mediators and Peptides useful Therein,” provides broad protection for methods of using another series of BioMarck’s anti-inflammatory peptides. These two new patents also provide broad protection for peptides and methods of treatment for a variety of pulmonary diseases involving mucus hypersecretion and airway inflammation. An extensive series of corresponding international patent applications has been or is being filed. “These two recently granted United States patents represent a significant milestone for BioMarck and they further strengthen BioMarck’s continually expanding intellectual property portfolio,” said Dr. Indu Parikh, President and Chief Scientific Officer of BioMarck Pharmaceuticals. BioMarck’s lead compound, BIO-11006 Inhalation Solution, is currently being tested in a multicenter, placebo-controlled, double-blind Phase 2 clinical study in COPD patients. The study is designed to enroll 162 patients with COPD, specifically chronic bronchitis. BioMarck initiated the study in the third quarter of 2008 and expects complete enrollment of the planned 162 patients to take 12 to 15 months. BioMarck is currently exploring potential partnerships with pharmaceutical companies with a significant presence in the respiratory field.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards